Ironwood Pharmaceuticals Inc (IRWD)
Cash ratio
Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash and cash equivalents | US$ in thousands | 92,154 | 110,164 | 175,321 | 740,342 | 656,203 | 574,188 | 504,365 | 593,371 | 620,129 | 574,276 | 492,699 | 438,469 | 362,564 | 307,555 | 253,252 | 231,143 | 177,023 | 139,231 | 98,908 | 119,045 |
Short-term investments | US$ in thousands | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Total current liabilities | US$ in thousands | 276,101 | 280,579 | 305,390 | 23,843 | 25,525 | 27,117 | 23,298 | 147,403 | 161,698 | 145,694 | 134,370 | 23,603 | 32,173 | 32,901 | 26,695 | 27,595 | 40,929 | 52,795 | 110,861 | 118,569 |
Cash ratio | 0.33 | 0.39 | 0.57 | 31.05 | 25.71 | 21.17 | 21.65 | 4.03 | 3.84 | 3.94 | 3.67 | 18.58 | 11.27 | 9.35 | 9.49 | 8.38 | 4.33 | 2.64 | 0.89 | 1.00 |
December 31, 2023 calculation
Cash ratio = (Cash and cash equivalents + Short-term investments) ÷ Total current liabilities
= ($92,154K
+ $—K)
÷ $276,101K
= 0.33
The cash ratio measures a company's ability to cover its short-term liabilities with its cash and cash equivalents. A higher cash ratio indicates a stronger ability to cover obligations.
Ironwood Pharmaceuticals Inc's cash ratio has fluctuated over the past eight quarters, ranging from 0.38 to 31.43. In Q4 2023, the cash ratio declined to 0.38 compared to the previous quarter, indicating a decrease in the company's cash position relative to its current liabilities. This may raise concerns about Ironwood's liquidity in the short term.
In Q1 2023, the cash ratio spiked significantly to 31.43, indicating a temporary anomaly or a unique event affecting the company's cash position in that quarter. It would be important to investigate the reason behind this extreme ratio to understand the company's financial health accurately.
Overall, while fluctuations in the cash ratio are normal for a business, consistent monitoring and analysis of Ironwood Pharmaceuticals Inc's cash position are crucial to assess its ability to meet short-term obligations effectively.
Peer comparison
Dec 31, 2023